Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

In a randomized trial of therapy for FMS-like tyrosine kinase-3 (FLT3) mutant acute myeloid leukemia in first relapse, 224 patients received chemotherapy alone or followed by 80 mg of the FLT3 inhibitor lestaurtinib twice daily. Endpoints included complete remission or complete remission with incomp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Levis, Mark, Ravandi, Farhad, Wang, Eunice S., Baer, Maria R., Perl, Alexander, Coutre, Steven, Erba, Harry, Stuart, Robert K., Baccarani, Michele, Cripe, Larry D., Tallman, Martin S., Meloni, Giovanna, Godley, Lucy A., Langston, Amelia A., Amadori, Sergio, Lewis, Ian D., Nagler, Arnon, Stone, Richard, Yee, Karen, Advani, Anjali, Douer, Dan, Wiktor-Jedrzejczak, W., Juliusson, Gunnar, Litzow, Mark R., Petersdorf, Stephen, Sanz, Miguel, Kantarjian, Hagop M., Sato, Takashi, Tremmel, Lothar, Bensen-Kennedy, Debra M., Small, Donald, Smith, B. Douglas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3069671/
https://ncbi.nlm.nih.gov/pubmed/21270442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-301796
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados